Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZQ-7: sourced facts only. name: "Furthermore, ZQ-7 was confirmed to covalently bind with the residue Ser132 of MAGL." [PMID:40107037]; target: "Furthermore, ZQ-7 was confirmed to covalently bind with the residue Ser132 of MAGL." [PMID:40107037]; developer: "Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei Key Laboratory of Industrial Microbiology, Wuhan 430068, China; Key Laboratory of Fermentation Engineering (Ministry of Education), Wuhan 430068, China, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China." [PMID:40107037]; stage: "Significantly increased 2-AG levels were detected in MDA-MB-231 cells treated with MAGL inhibitor ZQ-5, ZQ-6, ZQ-7, ZQ-19, and KML29, a previously identified MAGL covalent inhibitor." [PMID:40107037]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZQ-7.